Honasa Buys 58% of Fluence Pharma for ₹135 Cr, Launches Honasa Health for Nutraceuticals
Mamaearth parent Honasa Consumer is acquiring 58% of dermatologist-led nutraceuticals firm Fluence Pharma at a ₹135 crore enterprise value, with the remaining 42% to follow over 5-7 years. The board also cleared a wholly owned subsidiary, Honasa Health, to push B2C nutraceuticals across Hair Fact, Skin Fact and Pro Fact brands.
What happened
Honasa Consumer, parent of Mamaearth, will acquire 58% of nutraceuticals firm Fluence Pharma for ₹135 crore, with remaining 42% over 5-7 years. It also approved
Key facts
- 58% stake
- ₹135 crore EV
- 42% remaining over 5-7 years
- 3,000+ dermatologists
- FY25 revenue ₹37.21 cr
- share price ₹415.90
Why this matters
The phased 58/42 structure with a 5-7 year tail is a textbook earn-in template for founder-led health assets—worth benchmarking for any nutraceuticals or derma-adjacent targets in the pipeline.